Pacific Biosciences of California, which is developing a system that performs DNA sequencing using its proprietary single molecule real-time (SMRT) technology, filed on Monday with the SEC to raise up to $200 million in an initial public offering. The Menlo Park, CA-based company, which was founded in 2000 and is planning its commercial launch for early 2011, plans to list on the NASDAQ under the symbol PACB. J.P. Morgan and Morgan Stanley are the lead underwriters on the deal. No pricing terms were disclosed.
